

해외 바이오의약품 임상 현황 (2019.12.10~2019.12.23)

한국바이오의약품협회, 2019.12.24.
출처: ClinicalTrials.gov

○ 미국 40건

| NCT Number | Title | Conditions | Interventions | Sponsor/Collaborators | Phases |
|-------------|--|--|---|---|-----------------|
| NCT04208919 | Delayed Infusion of DCre in Living Donor Liver Transplantation | Living Donor Liver Transplantation | Biological: Donor-derived DCre | Angus W. Thomson PhD DSc University of Pittsburgh | Phase 1 Phase 2 |
| NCT04203641 | L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer | Pancreas Cancer | Biological: L-DOS47 Drug: Doxorubicin | Helix BioPharma Corporation Theradex | Phase 1 Phase 2 |
| NCT04084366 | Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors | Locally Advanced Solid Tumor | Drug: OBI-999 | OBI Pharma, Inc | Phase 1 Phase 2 |
| NCT04203875 | Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis | Autoimmune Hepatitis | Drug: Orencea (Abatacept) | Stuart Knechtle, M.D. Duke University | Phase 1 |
| NCT04177355 | Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults | HIV Infections | Biological: BG505 SOSIP.664 gp140 Biological: Placebo Biological: 3M-052-AF Biological: CpG 1018 Biological: GLA-LSQ Biological: Alum (Aluminum Hydroxide Suspension) | National Institute of Allergy and Infectious Diseases (NIAID) HIV Vaccine Trials Network International AIDS Vaccine Initiative Infectious Disease Research Institute (IDRI) Dynavax Technologies Corporation Fred Hutchinson Cancer Research Center | Phase 1 |
| NCT04176991 | Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia | Friedreich Ataxia | Biological: CTI-1601 Biological: Placebo | Chondrial Therapeutics, Inc. | Phase 1 |
| NCT04164069 | Dasatinib in Preventing Oxaliplatin-Induced Peripheral Neuropathy in Patients With Colorectal Cancer Receiving FOLFOX and Bevacizumab | Advanced Colorectal Carcinoma Metastatic Colorectal Carcinoma Stage IV Colorectal Cancer AJCC v8 Stage IVA Colorectal Cancer AJCC v8 Stage IVB Colorectal Cancer AJCC v8 Stage IVC Colorectal Cancer AJCC v8 | Biological: Bevacizumab Drug: Dasatinib Drug: Fluorouracil Drug: Leucovorin Drug: Leucovorin Calcium Drug: Oxaliplatin Other: Quality-of-Life Assessment | Anne Noonan National Cancer Institute (NCI) Ohio State University Comprehensive Cancer Center | Phase 1 |
| NCT04163952 | Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin | Locally Advanced Skin Squamous Cell Carcinoma Metastatic Skin Squamous Cell Carcinoma Recurrent Skin Squamous Cell Carcinoma | Biological: Panitumumab Biological: Talimogene Laherparepvec | Rutgers, The State University of New Jersey National Cancer Institute (NCI) | Phase 1 |
| NCT04139902 | PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor TSR-022 and PD-1 Inhibitor Dostarlimab (TSR-042) | Melanoma Stage III Melanoma Stage IV | Drug: Dostarlimab (TSR-042) (singly) Drug: Dostarlimab (TSR-042) and TSR-022 (combination) | Diwakar Davar Tesaro, Inc. University of Pittsburgh | Phase 2 |
| NCT04138277 | A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD | Pompe Disease (Late-onset) | Drug: AT2221 Biological: ATB200 | Amicus Therapeutics | Phase 3 |
| NCT04111666 | A Phase 1 Study in Healthy Volunteers for AL101 | Healthy | Biological: AL101 Other: Placebo | Alector Inc. | Phase 1 |
| NCT04061590 | Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-III A Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma Stage I Lung Cancer AJCC v8 Stage IA1 Lung Cancer AJCC v8 Stage IA2 Lung Cancer AJCC v8 Stage IA3 Lung Cancer AJCC v8 Stage IB Lung Cancer AJCC v8 Stage II Lung Cancer AJCC v8 Stage IIA Lung Cancer AJCC v8 Stage IIB Lung Cancer AJCC v8 Stage IIIA Lung Cancer AJCC v8 | Drug: Cisplatin Biological: Pembrolizumab Drug: Pemetrexed Drug: Pemetrexed Disodium Procedure: Therapeutic Conventional Surgery | University of California, San Francisco Merck Sharp & Dohme Corp. | Phase 2 |
| NCT03925532 | Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant | Allogeneic Hematopoietic Stem Cell Transplantation Recipient Osteopenia Osteoporosis | Biological: Denosumab | Roswell Park Cancer Institute Amgen | Phase 2 |
| NCT03807063 | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant | Acute Bilineal Leukemia Myelodysplastic/Myeloproliferative Neoplasm Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable Myeloproliferative Neoplasm Recurrent Acute Biphentotypic Leukemia Recurrent Acute Lymphoblastic Leukemia Recurrent Acute Myeloid Leukemia Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm Recurrent Chronic Lymphocytic Leukemia Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive Recurrent Chronic Myelomonocytic Leukemia Recurrent Myelodysplastic Syndrome | Biological: Rivogenlecleucel Drug: Rimiducid | Fred Hutchinson Cancer Research Center National Cancer Institute (NCI) Bellicum Pharmaceuticals | Phase 1 |
| NCT03794973 | Diabetes Autoimmunity Withdrawn in New Onset Patients (DAWN) | Diabetes Mellitus, Type 1 | Biological: TOL-3021 Other: TOL-3021 Placebo | Tolerion, Inc. | Phase 2 |
| NCT03314974 | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | Acute Leukemia Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Lymphoma Chronic Myelogenous Leukemia Plasma Cell Leukemia Myeloproliferative Neoplasms Myelofibrosis Myelodysplasia Refractory Anemia High Risk Anemia Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Marginal Zone B-Cell Lymphoma Follicular Lymphoma Lymphoplasmacytic Lymphoma Mantle-Cell Lymphoma Prolymphocytic Leukemia Diffuse Large Cell Non Hodgkins Lymphoma Lymphoblastic Lymphoma Burkitt Lymphoma High Grade Non-Hodgkin's Lymphoma, Adult Multiple Myeloma Juvenile Myelomonocytic Leukemia Biphentotypic/Undifferentiated/Prolymphocytic Leukemias MRD Positive Leukemia Natural Killer Cell Malignancies Acquired Bone Marrow Failure Syndromes | Biological: HSCT with TBI Regimen Biological: HSCT with Non-TBI Regimen | Masonic Cancer Center, University of Minnesota | Phase 2 |
| NCT04198766 | Study of INBRX-106 in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | Solid Tumor Non-Small Cell Lung Cancer Melanoma Head and Neck Cancer Gastric Cancer Renal Cell Carcinoma Urothelial Carcinoma | Drug: INBRX-106 - Hexavalent OX40 agonist antibody Drug: Pembrolizumab | Inhibrx, Inc. | Phase 1 |
| NCT04188379 | A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia. | Primary Immune Thrombocytopenia | Biological: efgartigimod Other: Placebo | argenx BVBA | Phase 3 |
| NCT04183335 | Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable | Neurodermatitis | Drug: Dupilumab SAR231893 Drug: Placebo Drug: Moisturizers Drug: Low to medium potent topical corticosteroids Drug: Topical calcineurin inhibitors | Sanofi Regeneron Pharmaceuticals | Phase 3 |
| NCT04143802 | A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM) | Diabetes Mellitus, Type 2 | Drug: LY3437943 Drug: Dulaglutide Drug: Placebo | Eli Lilly and Company | Phase 1 |
| NCT04098250 | Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH | Post-Traumatic Headache | Drug: Erenumab Other: Placebo | Mayo Clinic University of Arizona Translational Genomics Research Institute Arizona State University Phoenix VA Health Care System United States Department of Defense Amgen | Phase 2 |

해외 바이오의약품 임상 현황 (2019.12.10~2019.12.23)

한국바이오의약품협회, 2019.12.24.
출처: ClinicalTrials.gov

| | | | | | |
|-------------|--|--|---|---|-----------------|
| NCT04157517 | A Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics Study | Solid Neoplasms Carcinoma, Non-Small-Cell Lung Prostatic Neoplasms | Drug: TAK-573 | Millennium Pharmaceuticals, Inc. Takeda | Phase 1 |
| NCT04053764 | Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease | Sickle Cell Disease | Drug: Crizanlizumab Drug: Standard of Care | Novartis Pharmaceuticals Novartis | Phase 2 |
| NCT04066114 | Treg Modulation With CD28 and IL-6 Receptor Antagonists | Living-Donor Kidney Transplant Kidney Transplant Recipients | Biological: Iulizumab pegol Biological: antithymocyte globulin (rabbit) Drug: methylprednisolone Biological: tocilizumab Drug: Prednisone Drug: everolimus Biological: belatacept Drug: mycophenolate mofetil Drug: mycophenolic acid | National Institute of Allergy and Infectious Diseases (NIAID) Bristol-Myers Squibb Clinical Trials in Organ Transplantation | Phase 1 Phase 2 |
| NCT04201262 | An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD | Neuromyelitis Optica Neuromyelitis Optica Spectrum Disorder | Biological: Ravulizumab | Alexion Pharmaceuticals | Phase 3 |
| NCT04194944 | A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | Drug: Selpercatinib Drug: Carboplatin Drug: Cisplatin Drug: Pemetrexed Drug: Pembrolizumab | Eli Lilly and Company Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company | Phase 3 |
| NCT04189614 | An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer | Cancer Non-small Cell Lung Cancer (NSCLC) | Drug: Cofetuzumab Pelidotin | AbbVie Pfizer | Phase 1 |
| NCT04177108 | A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer. | Triple-Negative Breast Cancer | Drug: Atezolizumab Drug: Ipatasertib Drug: Paclitaxel Drug: Placebo for Atezolizumab Drug: Placebo for Ipatasertib | Hoffmann-La Roche | Phase 3 |
| NCT04129931 | PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study | Asthma | Drug: MCT Drug: Clazakizumab Drug: Broncho-Vaxom Drug: Imatinib Mesylate Drug: Cavosonstat Drug: Itacitinib Other: Placebo | University of North Carolina, Chapel Hill National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| NCT04206605 | Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) and Acquired Angioedema (AAE) Due to C1-INH Deficiency | Angioedema | Drug: Lanadelumab Other: Placebo | Shire | Phase 3 |
| NCT04150887 | Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia | Leukemia, Myeloid, Acute | Drug: Cusatuzumab Drug: Azacitidine Drug: Venetoclax | Janssen Research & Development, LLC argenx BVBA | Phase 1 |
| NCT04102098 | A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation | Carcinoma, Hepatocellular | Drug: Atezolizumab Drug: Bevacizumab | Hoffmann-La Roche | Phase 3 |
| NCT04100018 | A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer | Prostate Cancer | Biological: nivolumab Drug: prednisone Drug: docetaxel | Bristol-Myers Squibb | Phase 3 |
| NCT04075266 | A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis | Multiple Sclerosis | Drug: Ocrelizumab | Hoffmann-La Roche | Phase 2 |
| NCT04047628 | Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) | Relapsing Multiple Sclerosis Relapsing Remitting Multiple Sclerosis Secondary Progressive Multiple Sclerosis | Procedure: Autologous Hematopoietic Stem Cell Transplantation Biological: Best Available Therapy (BAT) | National Institute of Allergy and Infectious Diseases (NIAID) Immune Tolerance Network (ITN) | Phase 3 |
| NCT04004611 | A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC) | Ulcerative Colitis | Drug: Mirikizumab | Eli Lilly and Company | Phase 2 |
| NCT04196283 | A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Advanced Solid Tumors Cancer | Drug: ABBV-368 Drug: Tilsotolimod Drug: Nab-paclitaxel Drug: ABBV-181 | AbbVie Idera Pharmaceuticals, Inc. | Phase 1 |
| NCT03949855 | Belimumab With Rituximab for Primary Membranous Nephropathy | Membranous Nephropathy MN | Drug: Belimumab Drug: Placebo for Belimumab Drug: Rituximab | National Institute of Allergy and Infectious Diseases (NIAID) Immune Tolerance Network (ITN) GlaxoSmithKline | Phase 2 |
| NCT04159805 | A Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Participants With Generalized Myasthenia Gravis | Myasthenia Gravis | Drug: TAK-079 Drug: TAK-079 Placebo | Takeda | Phase 2 |
| NCT04148937 | A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer | Advanced Cancer | Drug: LY3475070 Drug: Pembrolizumab | Eli Lilly and Company | Phase 1 |

해외 바이오의약품 임상 현황 (2019.12.10~2019.12.23)

한국바이오의약품협회, 2019.12.24.
출처: ClinicalTrials.gov

○ 영국 7건

| NCT Number | Title | Conditions | Interventions | Sponsor/Collaborators | Phases |
|-------------|---|--|--|---|-----------------|
| NCT04201405 | Gene Therapy With Modified Autologous Hematopoietic Stem Cells for Patients With Mucopolysaccharidosis Type IIIA | Mucopolysaccharidosis Type IIIA | Drug: Autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene | University of Manchester Orchard Therapeutics CTI Clinical Trial and Consulting Services University College, London Great Ormond Street Hospital for Children NHS Foundation Trust Manchester University NHS Foundation Trust | Phase 1 Phase 2 |
| NCT04100018 | A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer | Prostate Cancer | Biological: nivolumab Drug: prednisone Drug: docetaxel | Bristol-Myers Squibb | Phase 3 |
| NCT04194944 | A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | Drug: Selpercatinib Drug: Carboplatin Drug: Cisplatin Drug: Pemetrexed Drug: Pembrolizumab | Eli Lilly and Company Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company | Phase 3 |
| NCT04149574 | A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) | Bladder Cancer | Drug: nivolumab Other: Placebo Biological: Bacillus Calmette-Guérin (BCG) | Bristol-Myers Squibb | Phase 3 |
| NCT04177108 | A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer. | Triple-Negative Breast Cancer | Drug: Atezolizumab Drug: Ipatasertib Drug: Paclitaxel Drug: Placebo for Atezolizumab Drug: Placebo for Ipatasertib | Hoffmann-La Roche | Phase 3 |
| NCT04148937 | A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer | Advanced Cancer | Drug: LY3475070 Drug: Pembrolizumab | Eli Lilly and Company | Phase 1 |
| NCT04047628 | Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) | Relapsing Multiple Sclerosis Relapsing Remitting Multiple Sclerosis Secondary Progressive Multiple Sclerosis | Procedure: Autologous Hematopoietic Stem Cell Transplantation Biological: Best Available Therapy (BAT) | National Institute of Allergy and Infectious Diseases (NIAID) Immune Tolerance Network (ITN) | Phase 3 |

○ 프랑스 6건

| NCT Number | Title | Conditions | Interventions | Sponsor/Collaborators | Phases |
|-------------|---|-------------------------------|--|--|---------|
| NCT04177108 | A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer. | Triple-Negative Breast Cancer | Drug: Atezolizumab Drug: Ipatasertib Drug: Paclitaxel Drug: Placebo for Atezolizumab Drug: Placebo for Ipatasertib | Hoffmann-La Roche | Phase 3 |
| NCT04100018 | A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer | Prostate Cancer | Biological: nivolumab Drug: prednisone Drug: docetaxel | Bristol-Myers Squibb | Phase 3 |
| NCT04148911 | A Study of Atezolizumab (Tecentriq) Plus Nab-Paclitaxel or Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer | Triple-Negative Breast Cancer | Drug: Atezolizumab Drug: Nab-Paclitaxel Drug: Paclitaxel | Hoffmann-La Roche | Phase 3 |
| NCT04194944 | A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | Drug: Selpercatinib Drug: Carboplatin Drug: Cisplatin Drug: Pemetrexed Drug: Pembrolizumab | Eli Lilly and Company Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company | Phase 3 |
| NCT04196283 | A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tisotumumab and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Advanced Solid Tumors Cancer | Drug: ABBV-368 Drug: Tisotumumab Drug: Nab-paclitaxel Drug: ABBV-181 | AbbVie Idera Pharmaceuticals, Inc. | Phase 1 |
| NCT04148937 | A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer | Advanced Cancer | Drug: LY3475070 Drug: Pembrolizumab | Eli Lilly and Company | Phase 1 |

○ 독일 5건

| NCT Number | Title | Conditions | Interventions | Sponsor/Collaborators | Phases |
|-------------|---|----------------------------|--|--|---------|
| NCT04187300 | A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity | Overweight Obesity | Drug: Semaglutide | Novo Nordisk A/S | Phase 1 |
| NCT04161976 | A Study of LY900027 Given by Insulin Pump to Participants With Type 1 Diabetes Mellitus | Diabetes Mellitus, Type 1 | Drug: LY900027 Drug: Insulin Lispro | Eli Lilly and Company | Phase 1 |
| NCT04100018 | A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer | Prostate Cancer | Biological: nivolumab Drug: prednisone Drug: docetaxel | Bristol-Myers Squibb | Phase 3 |
| NCT04194944 | A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | Drug: Selpercatinib Drug: Carboplatin Drug: Cisplatin Drug: Pemetrexed Drug: Pembrolizumab | Eli Lilly and Company Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company | Phase 3 |
| NCT04102098 | A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation | Carcinoma, Hepatocellular | Drug: Atezolizumab Drug: Bevacizumab | Hoffmann-La Roche | Phase 3 |

해외 바이오의약품 임상 현황 (2019.12.10~2019.12.23)

한국바이오의약품협회, 2019.12.24.
출처: ClinicalTrials.gov

○ 일본 1건

| NCT Number | Title | Conditions | Interventions | Sponsor/Collaborators | Phases |
|-------------|---|---------------------------|--------------------------------------|-----------------------|---------|
| NCT04102098 | A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation | Carcinoma, Hepatocellular | Drug: Atezolizumab Drug: Bevacizumab | Hoffmann-La Roche | Phase 3 |
| NCT04004611 | A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC) | Ulcerative Colitis | Drug: Mirikizumab | Eli Lilly and Company | Phase 2 |

○ 중국 9건

| NCT Number | Title | Conditions | Interventions | Sponsor/Collaborators | Phases |
|-------------|---|--|---|--|-----------------|
| NCT04202601 | Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer | Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | Drug: Sintilimab Drug: IBI310 | Peking University Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 Phase 2 |
| NCT04191889 | A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification | C-staged Hepatocellular Carcinoma in BCLC Classification | Combination Product: Hepatic Arterial Infusion combined with Apatinib and Camrelizumab | Sun Yat-sen University Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| NCT04189276 | Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) Combined With Nucleoside (Acid) Analogues in Chronic Hepatitis B Patients | Hepatitis B Virus (HBV) | Biological: ETV/TDF+T101 No.1 Biological: ETV/TDF+T101 No.2 Biological: ETV or TDF Biological: ETV/TDF+Peg-IFN-2b | Tasly Tianjin Biopharmaceutical Co., Ltd. | Phase 2 |
| NCT04175847 | A Phase I Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors | Solid Tumor | Drug: RC88 | RemeGen | Phase 1 |
| NCT04099303 | Phase I Clinical Trial of One Vaccine | Diphtheria Tetanus Pertussis | Biological: Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed Biological: Diphtheria and Tetanus Combined Vaccine, Adsorbed Biological: Diphtheria-tetanus-acellular pertussis vaccine Biological: Diphtheria,tetanus,pertussis(acellular,component),poliomyelitis(inactivate d) vaccine(adsorbed) and Haemophilus influenzae type b conjugate vaccine | CanSino Biologics Inc. Henan Center for Disease Control and Prevention | Phase 1 |
| NCT04177823 | A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | Multiple Myeloma | Drug: Belantamab mafodotin | GlaxoSmithKline | Phase 1 |
| NCT04194944 | A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | Drug: Selpercatinib Drug: Carboplatin Drug: Cisplatin Drug: Pemetrexed Drug: Pembrolizumab | Eli Lilly and Company Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company | Phase 3 |
| NCT04102098 | A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation | Carcinoma, Hepatocellular | Drug: Atezolizumab Drug: Bevacizumab | Hoffmann-La Roche | Phase 3 |
| NCT04100018 | A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer | Prostate Cancer | Biological: nivolumab Drug: prednisone Drug: docetaxel | Bristol-Myers Squibb | Phase 3 |